Bayer focus shifts from German headquarters back to US courts

As Bayer management digs in against a growing shareholder rebellion over the acquisition of Monsanto, attention will shift from the German company’s headquarters back to US courts.

That’s where the German pharma and chemicals giant faces 13,400 lawsuits claiming that Monsanto’s Roundup weedkiller causes cancer. Even as it fights the cases, the company’s shareholders handed chief executive officer Werner Baumann an unprecedented rebuke last week.